Literature DB >> 8479324

Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

R Cervera1, M A Khamashta, J Font, G D Sebastiani, A Gil, P Lavilla, I Doménech, A O Aydintug, A Jedryka-Góral, E de Ramón.   

Abstract

In the present study we have analyzed the prevalence and characteristics of the most relevant clinical and immunologic features in 1,000 patients with SLE. Several differences in the expression of the disease have been observed in relation to the patients' age at onset, sex, and autoantibody serology. The childhood-onset patients more often had malar rashes (55% vs 39%) and nephropathy (28% vs 15%) as presenting manifestations. During the evolution of the disease, these patients had an increased prevalence only of malar rash (79% vs 56%) and a lower prevalence of rheumatoid factor (6% vs 19%). The older-onset patients (age 50 or older) less often showed malar rash (21% vs 42%), arthritis (52% vs 71%), and nephropathy (3% vs 17%) as the first symptom. During the evolution of their disease, these patients had a decreased prevalence of malar rash (33% vs 60%), photosensitivity (29% vs 47%), arthritis (73% vs 85%), nephropathy (22% vs 41%), thrombosis (4% vs 15%), and anti-La antibodies (6% vs 20%), but an increased prevalence of sicca syndrome (33% vs 15%). Males more often had serositis (28% vs 16%) as a first symptom, but they presented with a lower prevalence of arthritis (74% vs 85%) during the evolution of the disease. The presence of ANA, a high titer of anti-dsDNA, rheumatoid factor, anti-ENA, and antiphospholipid antibodies also distinguished additional homogeneous SLE subsets of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479324

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  185 in total

Review 1.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 2.  The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.

Authors:  M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  J Neurol       Date:  2011-12-08       Impact factor: 4.849

Review 3.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 4.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

5.  Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.

Authors:  R Cervera; O Viñas; M Ramos-Casals; J Font; M García-Carrasco; A Sisó; F Ramírez; Y Machuca; J Vives; M Ingelmo; R W Burlingame
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 6.  Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment.

Authors:  Laurent Arnaud; Alexis Mathian; Jacques Boddaert; Zahir Amoura
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

Review 7.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

8.  Severe human monocytic ehrlichiosis presenting with altered mental status and seizures.

Authors:  Christian Geier; Jessica Davis; Marc Siegel
Journal:  BMJ Case Rep       Date:  2016-10-06

9.  Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

Authors:  D Paran; J Chapman; A D Korczyn; O Elkayam; O Hilkevich; G B Groozman; D Levartovsky; I Litinsky; D Caspi; Y Segev; V E Drory
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

10.  Hypersensitivity to molybdenum as a possible trigger of ANA-negative systemic lupus erythematosus.

Authors:  M Federmann; B Morell; G Graetz; M Wyss; P Elsner; R von Thiessen; B Wüthrich; D Grob
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.